Navigation Links
Heska Announces Financial Results for the First Quarter of Fiscal 2013
Date:5/14/2013

LOVELAND, Colo., May 14, 2013 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a provider of advanced veterinary diagnostic and other specialty veterinary products, today reported financial results for its first quarter ended March 31, 2013. The Company previously announced the acquisition of 54.6% of Cuattro Vet US, LLC ("Cuattro Vet USA").

First Quarter 2013 Highlights:

  • Consolidated revenue decreased 1% to $19.0 million compared to $19.2 million in the first quarter of 2012.
  • Core Companion Animal Health revenue decreased approximately 6%, while Other Vaccines, Pharmaceuticals and Products revenue increased 28% as compared to the first quarter of 2012.
  • Gross profit decreased 12.6% year-over-year and gross margin was 41.1% compared to 46.5% in the first quarter of 2012.
  • The Company reported an operating loss of $682 thousand compared to operating income of $1.1 million in the first quarter of 2012.
  • Heska completed the quarter with $5.5 million in cash, $6.1 million in short-term debt and $12.2 million in working capital.
  • "The first quarter was a milestone period for Heska, highlighted by our majority acquisition of Cuattro Vet USA at the end of February," commented Robert Grieve , Heska's Chairman and CEO. "This transformative acquisition provided us with access to a growing company with a best-in-class imaging product line powered by state-of-the-art software. We are now able to combine imaging products, such as digital x-ray and ultrasound, with Heska's existing capital equipment used for blood analysis, including chemistry and hematology, in coordinated sales efforts. Finally, we acquired proven talent, both in senior leadership and in sales execution surrounding capital equipment. The Cuattro Vet USA team has a proven track record in creatively and successfully developing and executing go-to-market strategies for capital equipment, and this fills a key need for Heska. We achieved this via a creative transaction structure which enabled us to maintain our net operating loss carry-forward asset with a minimal dilution of our common stock."

    Dr. Grieve concluded, "Our current strategic focus is on optimizing the Cuattro Vet USA opportunity and transitioning our commercial strategies and tactics. As we make progress in these efforts, we are very excited about the growth opportunities in 2014 and beyond."

    Financial Results
    First quarter 2013 revenue was $19.0 million as compared to $19.2 million in the first quarter of 2012. In the first quarter of 2013, Core Companion Animal Health revenue decreased approximately 6% to $15.6 million from $16.6 million in the prior year period and Other Vaccines, Pharmaceuticals and Products revenue grew approximately 28% to $3.3 million. Gross profit was $7.8 million, or a 41.1% gross margin, in the first quarter of 2013 compared with gross profit of $8.9 million, or 46.5% gross margin, in the first quarter of 2012. Total operating expenses were $8.5 million, or 44.7% of sales, in the first quarter of 2013 compared with total operating expenses of $7.8 million, or 40.9% of sales, in the prior year period. The Company reported an operating loss of $682 thousand in the first quarter of 2013, compared to operating income of $1.1 million in the first quarter of 2012. Loss before income taxes was $671 thousand in the first quarter of 2013, down from income of $940 thousand in the prior year period. In the first quarter of 2013, net loss was $352 thousand, or $0.06 per diluted share, compared to net income of $584 thousand, or $0.11 per diluted share, in the first quarter of 2012.

    Balance Sheet
    As of March 31, 2013, Heska had $5.5 million in cash and working capital of $12.2 million. Stockholders' equity increased to $52.0 million compared to $48.9 million as of December 31, 2012.

    Investor Conference Call
    Management will conduct a conference call on Tuesday, May 14, 2013 at 2:30 p.m. MDT (4:30 p.m. EDT) to discuss the first quarter 2013 financial results. To participate, dial (877) 941-8609 (domestic) or (480) 629-9692 (international); the conference call access number is 4613897. The conference call will also be broadcast live over the Internet at http://www.heska.com. To listen, simply log on to the web at this address at least ten minutes prior to the start of the call to register, download and install any necessary audio software. Telephone replays of the conference call will be available for playback on Heska's home page at www.heska.com until May 28, 2013. The telephone replay may be accessed by dialing (800) 406-7325 (domestic) or (303) 590-3030 (international). The replay access number is 4613897.

    About Heska
    Heska Corporation (NASDAQ: HSKA - News) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single-use, point-of-care tests, pharmaceuticals and vaccines. The Company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians. For further information on Heska and its products, visit the company's website at www.heska.com.

    Forward-Looking Statements
    This announcement contains forward-looking statements regarding Heska's future financial and operating results, including Cuattro Veterinary USA, LLC, which was recently renamed Heska Imaging US, LLC ("Cuattro Vet USA"). These statements are based on current expectations and are subject to a number of risks and uncertainties. Investors should note that there is an inherent risk in using past results, including trends, to predict future outcomes. In addition, factors that could affect the business and financial results of Heska generally include the following: uncertainties related to the future success of any acquisition, including Cuattro Vet USA, of which Heska owns 54.6%; uncertainties related to Heska's future ownership position in Cuattro Vet USA as a third party has the right to repurchase Heska's 54.6% interest; uncertainties related to Heska's ability to successfully market and sell its products in an economically sustainable manner; risks related to Heska's ability to utilize its domestic net operating loss tax carryforward position; uncertainties related to the future business performance impact of reductions in selling expenses; risks related to uncertainties related to Heska's ability to generate increased sales and profits due to any coordinated product selling strategy with Cuattro Vet USA; uncertainties related to the performance and brand image of Cuattro Vet USA's product and service offerings; competition; uncertainties related to the commercialization of products Heska may introduce in the future, such as market acceptance; risks related to Heska's reliance on third party suppliers, which is substantial; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Annual Report on Form 10-K for the year ended December 31, 2012.

    Financial Table Follows: Consolidated Statements of Operations

    In Thousands, Except per Share Amounts

    (unaudited)Three Months Ended

    March 31,20122013Revenue:Core companion animal health$

    16,580$

    15,649Other vaccines, pharmaceuticals and products2,5953,330Total revenue, net 19,17518,979Cost of revenue10,25211,177Gross profit8,9237,802Operating expenses:Selling and marketing4,8885,125Research and development334390General and administrative2,6192,969Total operating expenses7,8418,484Operating income (loss)1,082(682)Interest and other (income) expense, net142(11)Income (loss) before income taxes940(671)Income tax expense: Current tax expense 486Deferred tax expense (benefit)308(325)Total income tax expense356(319)Net income (loss) $

    584$

    (352)Net income attributable to non-controlling interest—34Net income (loss) attributable to Heska Corporation584(386)Basic net income (loss) per share attributable to Heska Corporation$

    0.11$

    (0.07)Diluted net income (loss) per share attributable to Heska Corporation$

    0.11$

    (0.07)Shares used for basic net income (loss) per share attributable to Heska Corporation5,2645,547Shares used for diluted net income (loss) per share attributable to Heska Corporation5,4345,547 

     

    Balance Sheet Data

    In Thousands (unaudited)December 31,

    2012March 31,

    2013Cash and cash equivalents$

    5,784$

    5,459Total current assets32,95532,089Note receivable-related party—1,364Total assets66,82689,564Line of credit2,5525,106Other short-term borrowings, including current portion of long-term note payable—982Total current liabilities14,38919,909Long-term note payable, net of current portion—468Non-controlling interest—12,003Public Common Stock subject to redemption—3,894Stockholders' equity48,86248,057 


    '/>"/>
    SOURCE Heska Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Heska Announces Quarterly Dividend of $0.10 Per Share
    2. Heska to Present at B. Riley Investor Conference
    3. Heska Corporation Announces Amendment To Its Odd-Lot Tender Offer
    4. Webcast Alert: Heska Announces Third Quarter 2012 Earnings Conference Call Webcast
    5. Heska Enters Distribution Agreement with MWI Veterinary Supply
    6. Heska Reports Third Quarter 2012 Earnings
    7. Webcast Alert: Heska Announces Fourth Quarter and Year-End 2012 Earnings Conference Call Webcast
    8. Heska Announces 19.0% Revenue Growth for Fourth Quarter of Fiscal 2012
    9. Webcast Alert: Heska Corporations Annual Meeting of Stockholders Webcast
    10. Heska Corporation to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
    11. Heska Corporation to Present at the 14th Annual B. Riley & Co. Investor Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
    (Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
    (Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
    Breaking Medicine Technology:
    (Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
    (Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
    (Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
    (Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
    (Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
    Breaking Medicine News(10 mins):